Sandoz Decides Not To Pursue US Biosimilar Rituximab; Will Focus On Robust Biosimilar Portfolio For Unmet Access And Sustainability Needs 글 내용 전체보기
AbbVie Announces VENCLYXTO® (venetoclax) Plus Rituximab Receives European Commission Approval 글 내용 전체보기
FDA cited Akorn’s New Jersey plant even as drugmaker fought Fresenius in court over abandoned buyout 글 내용 전체보기
That generic Advair you’ve been expecting for months? It’ll come, but let’s talk other products, Mylan says 글 내용 전체보기
Eylea crosses quarterly U.S. blockbuster line for Regeneron as Dupixent nears new FDA expansion 글 내용 전체보기
